TrialReader


Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache

NCT03112720 — Phase 3, Terminated, 8 participants, Rutgers, The State University of New Jersey

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Comparison of the Efficacy of Sphenopalatine Ganglion (SPG) Block With 5% Lidocaine Versus Epidural Blood Patch (EBP) for the Treatment of Post-Dural Puncture Headache (PDPH)

RegistryNCT03112720
StatusTerminated - no enrollment after covid pandemic
PhasePhase 3
Study typeInterventional; randomized, parallel, masking: none, treatment
Enrollment8 (Actual)
SponsorRutgers, The State University of New Jersey (Other); collaborators: New Jersey Medical School
ConditionsPostdural Puncture Headache
InterventionsEpidural Blood Patch, Sphenopalatine Ganglion Block (Device, drug)
Datesstart 2016-09-01, primary completion 2020-09-01, completion 2020-09-01, first posted 2017-04-13, last updated 2023-06-22
Locations2 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Postdural Puncture Headache All trials of Epidural Blood Patch All trials of Sphenopalatine Ganglion Block

-Summary

The purpose of this study is to compare a pain block in the midface, versus the traditional, more invasive, therapeutic epidural patch for the treatment of headaches

Expand all sections  ·  Collapse all

+Detailed description

The sphenopalatine nerve block has been used to treat headaches. Patients have headaches after epidural access from post dural puncture. We need to know if sphenopalatine nerve block will help the patient with the headache.

+Arms and interventions

ArmTypeInterventionsDescription
Epidural blood patchActive comparatorDevice: Epidural Blood Patch20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
Sphenopalatine Ganglion BlockExperimentalDrug: Sphenopalatine Ganglion BlockCotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
  • Epidural Blood Patch (Device): A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
  • Sphenopalatine Ganglion Block (Drug): The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.

+Outcome measures

Primary outcomes

  • Number of Headaches With a VAS Score >8/10 Prior to Initiation of Either Therapy [Prior to initiation of therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).]: Outcome measure will entail recording patient self-reported pain scores to quantify the level of headache pain using the Visual analog scale, meaning 0 - No pain, 1-3 - Mild Pain, 4-6 - Moderate Pain, 7-10 - Severe Pain, by way of in person assessment by pain questionnaire just prior to initiation of either therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).
  • Number of Participants With a Headache Vas 8/10 at 30 Minutes Following Either Therapy. [At 30 minutes following either therapy.]: Self-reported pain scores to quantify the level of headache pain using the Visual analog scale (as defined within the description of outcome 1 above) by way of in person assessment by pain questionnaire at 30 minutes following either therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).
  • Number of Participants With a Headache Vas 8/10 at 60 Minutes Following Either Therapy. [At 60 minutes following either therapy.]: Self-reported pain scores to quantify the level of headache pain using the Visual analog scale (as defined within the description of outcome 1 above) by way of in person assessment by pain questionnaire at 60 minutes following either therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).

+Eligibility

Sex: All, ages: 13 Years to 92 Years, accepts healthy volunteers

Inclusion Criteria:

* Males and females ages 13-92
* Subjects have medical diagnosis of PDPH and require treatment
* Subjects who signed consent/assent

Exclusion Criteria:

* <13 years of age
* Pregnancy
* Subjects with heart failure
* Subjects already being treated with lidocaine patch or other vehicle for chronic pain
* Non-english speaking subjects
* Subjects with platelets <100,000
* Subjects that are septic
* Subjects with an allergy to lidocaine
* Subjects with known nasal polyps
* Subjects with recent neurological event
* Subjects on anticoagulant therapy
* Subjects that received prior therapy with SPG block or EBP

+Posted results

Participant flow

MilestoneEpidural Blood Patch GroupSphenopalatine Ganglion Block Group
Started53
Completed53
Not completed00

Outcome results

  • Number of Headaches With a VAS Score >8/10 Prior to Initiation of Either Therapy (Primary), Number, headache with VAS >8/10: Epidural Blood Patch Group 1; Sphenopalatine Ganglion Block Group 1
  • Number of Participants With a Headache Vas 8/10 at 30 Minutes Following Either Therapy. (Primary), Count of participants, Participants: Epidural Blood Patch Group 1; Sphenopalatine Ganglion Block Group 1
  • Number of Participants With a Headache Vas 8/10 at 60 Minutes Following Either Therapy. (Primary), Count of participants, Participants: Epidural Blood Patch Group 1; Sphenopalatine Ganglion Block Group 0 (p <0.01)

Adverse events

Time frame: 48 hours

ArmDeathsSerious adverse eventsOther adverse events
Epidural Blood Patch Group0/5 (0.0%)0/5 (0.0%)0/5 (0.0%)
Sphenopalatine Ganglion Block Group0/3 (0.0%)0/3 (0.0%)0/3 (0.0%)

+Locations (2)

FacilityCityCountryStatus
New Jersey Pain CenterNew Brunswick, New JerseyUnited States
RWJUH/BarnabusNew Brunswick, New JerseyUnited States

+Study documents

+Investigators

My Notes